Beijing Leadman Biochemistry reports H1 loss amid fierce competition

Beijing Leadman Biochemistry Co., Ltd. released its 2025 semi-annual report, approved on August 26, 2025. The report indicates total operating revenue of 160,484,126.32 yuan, a decrease of 14.80% compared to the previous year, with a net loss attributable to shareholders of -4,245,185.53 yuan. This decline is attributed to increased industry competition, the implementation of volume-based procurement policies for diagnostic reagents, and the unbundling of testing packages.

The company also disclosed significant related party transactions. In the first half of 2025, various related party transactions, including purchases of goods and services, were reported, with amounts such as 796.46 yuan to Anhui Ruiyue Medical Technology Co., Ltd. for reagents and 110,932.62 yuan for property management fees to Guangzhou Kaiyun Smart Services Co., Ltd.

In an effort to mitigate market risks and enhance competitiveness, Beijing Leadman Biochemistry is focusing on optimizing its internal operational management, reducing costs, and improving efficiency. The company plans to pursue technological innovation, lower expenses, and develop specialized diagnostic projects while expanding its upstream and downstream collaborations to achieve external growth. As of the end of the reporting period, the company has no plans to distribute cash dividends, bonus shares, or convert capital reserves into share capital.